11 | EFFICACY AND SAFETY OF LEBRIKIZUMAB IS MAINTAINED UP TO 4 YEARS IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: FIRST YEAR OF ADLONG LONG-TERM EXTENSION TRIAL

L. Stingeni¹, S. Weidinger², A. Irvine³, D. Thaçi⁴, J. Szepietowski⁵, T. Biedermann⁶, H. Agell⁷, Y. Mihaylov⁷, B. Kostov⁷, R. Coll⁷, W. Romero⁸, K. Reich⁹ | ¹Dermatology Section, Department of Medicine and Surgery, University of Perugia, Italy; ²Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; ³Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland; ⁴Institute and Comprehensive Center for Inflammatory Medicine at the University of Lübeck, Lübeck, Germany; ⁵Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wrocław University of Science and Technology, Wrocław, Poland; ⁶Department of Dermatology and Allergy, Technical University of Munich, School of Medicine and Health, Munich, Germany; ⁷Almirall S.A., Barcelona, Spain; ⁸Eli Lilly and Company, Indianapolis, IN, USA; ⁹Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

Long-term data from advanced treatments in atopic dermatitis (AD) are important to inform clinical practice. Lebrikizumab (LEB) is approved by the FDA and EMA for treating moderate-to-severe (mod-sev) AD in adults and adolescents who are candidates for systemic therapy(1|2). Here we report long-term safety and efficacy from the first 48 weeks (W) of the ongoing 2-year ADlong long-term extension study (NCT05916365), including patients (pts) with up to 4 years’ continuous LEB exposure. ADlong evaluated long-term safety and efficacy of LEB following completion of ADvocate1&2(3)/ADhere/ADore and the ADjoin extension study(4) (up to 3 years’ LEB exposure). Eligible pts to parent studies were adults and adolescents (12–17 years, ≥40kg) with mod-sev AD (Eczema Area and Severity Index [EASI] ≥16, Investigator’s Global Assessment [IGA] ≥3, ≥10% body surface area AD involvement). Pts in Germany and Poland who completed ADjoin could enrol in ADlong, excluding those whose last LEB dose was administered >8W before baseline or developed a LEB-related serious/severe adverse event (SAE). In ADlong, pts received open-label LEB 250 mg once every four weeks (Q4W) regardless of their previous treatment; LEB Q2W could be used if response was